Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Operating Expenses (2017 - 2019)

Historic Operating Expenses for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to $1.2 million.

  • Monopar Therapeutics' Operating Expenses rose 3222.7% to $1.2 million in Q4 2019 from the same period last year, while for Sep 2020 it was $1.2 million, marking a year-over-year decrease of 6956.95%. This contributed to the annual value of $4.3 million for FY2019, which is 2979.8% up from last year.
  • According to the latest figures from Q4 2019, Monopar Therapeutics' Operating Expenses is $1.2 million, which was up 3222.7% from $759448.0 recorded in Q3 2019.
  • In the past 5 years, Monopar Therapeutics' Operating Expenses ranged from a high of $14.9 million in Q3 2017 and a low of $373839.0 during Q1 2017
  • Its 3-year average for Operating Expenses is $2.0 million, with a median of $828354.0 in 2018.
  • Examining YoY changes over the last 5 years, Monopar Therapeutics' Operating Expenses showed a top increase of 14001.24% in 2018 and a maximum decrease of 9551.92% in 2018.
  • Over the past 3 years, Monopar Therapeutics' Operating Expenses (Quarter) stood at $736800.0 in 2017, then increased by 25.73% to $926358.0 in 2018, then skyrocketed by 32.23% to $1.2 million in 2019.
  • Its Operating Expenses stands at $1.2 million for Q4 2019, versus $759448.0 for Q3 2019 and $932109.0 for Q2 2019.